Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2014128198) BILATERALLY-SUBSTITUTED TRICYCLIC COMPOUNDS FOR THE TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS TYPE-1 (HIV-1) INFECTION AND OTHER DISEASES
Latest bibliographic data on file with the International Bureau   

Pub. No.: WO/2014/128198 International Application No.: PCT/EP2014/053294
Publication Date: 28.08.2014 International Filing Date: 20.02.2014
Chapter 2 Demand Filed: 19.12.2014
IPC:
C07C 213/02 (2006.01) ,C07C 217/60 (2006.01) ,A61K 31/137 (2006.01) ,A61K 31/14 (2006.01) ,A61P 31/14 (2006.01) ,A61P 31/18 (2006.01) ,A61P 31/04 (2006.01) ,A61P 35/00 (2006.01)
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
C
ACYCLIC OR CARBOCYCLIC COMPOUNDS
213
Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton
02
by reactions involving the formation of amino groups from compounds containing hydroxy groups or etherified or esterified hydroxy groups
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
C
ACYCLIC OR CARBOCYCLIC COMPOUNDS
217
Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
54
having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
56
with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms
60
linked by carbon chains having two carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
13
Amines, e.g. amantadine
135
having aromatic rings, e.g. methadone
137
Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
13
Amines, e.g. amantadine
14
Quaternary ammonium compounds, e.g. edrophonium, choline
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
31
Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
12
Antivirals
14
for RNA viruses
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
31
Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
12
Antivirals
14
for RNA viruses
18
for HIV
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
31
Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
04
Antibacterial agents
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35
Antineoplastic agents
Applicants:
CENTRO DE INVESTIGACIÓN PRÍNCIPE FELIPE [ES/ES]; Carrer d´Eduardo Primo Yúfera, 5 E-46012 Valencia, ES
INSTITUTO DE SALUD CARLOS III [ES/ES]; Avenida de Monforte de Lemos, 5 E-28029 Madrid, ES
UNIVERSIDAD CATÓLICA DE VALENCIA "SAN VICENTE MÁRTIR" [ES/ES]; Quevedo, 2 E-46001 Valencia, ES
UNIVERSITAT DE VALÈNCIA [ES/ES]; Avda. Blasco Ibañez, 13 E-46010 Valencia, ES
Inventors:
GALLEGO SALA, José; ES
FUSTERO LARDIÉS, Santos; ES
ALCAMÍ PERTEJO, José; ES
GONZÁLEZ BULNES, Luis; ES
IBAÑEZ SÁNCHEZ, Ignacio; ES
CATALÁN MUÑOZ, Silvia; ES
PRADO MARTÍN, Silvia; ES
CANTERO CAMACHO, Ángel; ES
BARRIO FERNÁNDEZ, Pablo; ES
Agent:
FERNANDEZ ARIZPE, Almudena; ABG Patentes, S. L. Avenida de Burgos, 16D - Edificio Euromor E-28036 Madrid, ES
Priority Data:
20133023521.02.2013ES
Title (EN) BILATERALLY-SUBSTITUTED TRICYCLIC COMPOUNDS FOR THE TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS TYPE-1 (HIV-1) INFECTION AND OTHER DISEASES
(FR) COMPOSÉS TRICYCLIQUES BILATÉRALEMENT SUBSTITUÉS POUR LE TRAITEMENT D'UNE INFECTION AU VIRUS DE L'IMMUNODÉFICIENCE HUMAINE DE TYPE 1 (VIH-1) ET AUTRES MALADIES
Abstract:
(EN) The invention relates to bilaterally-substituted tricyclic compounds and pharmaceutical compositions containing them, for use as medicaments. Due to their ability to interact with an internal RNA loop and to mimic a protein a-helix these compounds are effective in the treatment and/or prevention of HIV-1 (Human Immunodeficiency Virus-1) infection and other diseases such as those caused by other RNA viruses and by gram-positive and gram-negative bacteria, or infectious or chronic diseases responsive to inhibition of DNA transcription, or infectious or chronic diseases where these compounds can be used to modulate the function of RNA internal loops, or infectious or chronic diseases where these compounds can be used as agonists or inhibitors of a-helical proteins in interaction with other biomolecules.
(FR) La présente invention concerne des composés tricycliques bilatéralement substitués et des compositions pharmaceutiques les contenant, destinés à être utilisés comme médicaments. En raison de leur aptitude à interagir avec une boucle interne d'ARN et à imiter une hélice alpha de protéine, ces composés sont efficaces dans le traitement et/ou la prévention de l'infection au VIH-1 (virus de l'immunodéficience humaine de type 1) et autres maladies comme celles provoquées par des virus à ARN et par des bactéries à Gram positif et à Gram négatif, ou des maladies infectieuses ou chroniques répondant à l'inhibition de la transcription de l'ADN, ou des maladies infectieuses ou chroniques dans lesquelles ces composés peuvent être utilisés pour moduler la fonction des boucles internes de l'ARN, ou des maladies infectieuses ou chroniques dans lesquelles ces composés peuvent être utilisés comme agonistes ou inhibiteurs de protéines à hélice alpha en interaction avec d'autres biomolécules.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)